Loading patent…
AssigneeNational University Corporation Chiba University
InventorsToshinori NAKAYAMA, Hiroyuki HOSOKAWA, Koji TOKOYODA, Koji HAYASHIZAKI, Akane SUZUKI
Estimating the term…
Provided is a means for inhibiting a function of CD69, whereby allowing suppression of an inflammatory response. That is, provided are: a composition for treating an inflammatory disease which includes an antibody that specifically recognizes a myosin regulatory light chain polypeptide (hereinafter abbreviated as Myl), preferably Myl9, Myl12a, and Myl12b, and inhibits a result of an effect of coexistence of Myl with CD69; a method of treating an inflammatory disease, including administering, to a subject diagnosed as having an inflammatory disease, a therapeutically effective amount of the antibody; and a method of identifying a compound that inhibits a result of an effect of coexistence of Myl with CD69, and a method of identifying a candidate compound for treating an inflammatory disease, including selecting a compound that inhibits the result.
A composition for treating an inflammatory disease, comprising an antibody that specifically recognizes a myosin regulatory light chain polypeptide (which is hereinafter abbreviated as Myl) and inhibits a result of an effect of coexistence of Myl with CD69.
A method of identifying a compound that inhibits a result of an effect of coexistence of Myl with CD69, comprising:
A method of identifying a candidate compound that serves as an active ingredient of a composition for treating an inflammatory disease, comprising
A method of treating an inflammatory disease, comprising
Dependencies are inferred from the claim text.